Coverage-gated living condition brief

Obesity peptide evidence brief

A cited Obesity peptide evidence brief across 141 exact-label ClinicalTrials.gov records, 27 connected profiles, and 16 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.

Registry records

141 selected records.

Connected peptides

27 profiles.

Registry update years

2008–2026 in selected records.

Direct collection answer · published August 17, 2026

What peptide evidence does PeptideScanner carry for Obesity?

PeptideScanner’s selected collection contains 141 retained ClinicalTrials.gov records carrying the exact condition label “Obesity,” connected to 27 peptide profiles across 16 registry-update years.

That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Obesity, and it is not a safety or efficacy assessment.

Indication intelligence

Selected evidence landscape

Trial phases6

Phase labels copied from the retained ClinicalTrials.gov versions.

Registry statuses5

Overall statuses at each retained observation, not necessarily current today.

Across the connected peptide profiles, PeptideScanner also carries 798 selected PubMed records and 77 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Obesity unless their own cited source says so.

Related profile context

Literature connected through these peptide profiles

All literature facets →

This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Obesity.

Eloralintide · source record 2026-08-15

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.

PubMed lists PMID 41559929 in Diabetes, obesity & metabolism as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase I, Multicenter Study, with publication-date metadata of 2026-01-20 (day precision). PeptideScanner associated the retained record with the identity slug eloralintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Maridebart cafraglutide · source record 2026-08-13

Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.

PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Orforglipron · source record 2026-11-09

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.

PubMed lists PMID 41994902 in Diabetes, obesity & metabolism as Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Collection change ledger

Recently changed records on this condition hub

All recent changes →

These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.

Record added

ClinicalTrials.gov record NCT00392925

PeptideScanner retained ClinicalTrials.gov record NCT00392925 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was metreleptin.

PeptideScanner change date
November 16, 2026
Cited source date
April 14, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00394667

PeptideScanner retained ClinicalTrials.gov record NCT00394667 at 2026-11-16T17:29:46.323Z. Its registry update date was 2013-04-22, and PeptideScanner's reviewed identity mapping was tesofensine.

PeptideScanner change date
November 16, 2026
Cited source date
April 22, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00428415

PeptideScanner retained ClinicalTrials.gov record NCT00428415 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-05, and PeptideScanner's reviewed identity mapping was tesofensine.

PeptideScanner change date
November 16, 2026
Cited source date
March 5, 2008
Evidence lane
Clinical trials

Exact-record source chronology

Obesity registry timeline

All trial facets →

Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.

2026

112 records

2025

3 records

2024

1 record

2023

2 records

2022

2 records

2021

2 records

2020

4 records

2019

1 record

2018

2 records

2017

3 records

2016

1 record

2015

2 records

2014

1 record

2013

3 records

2011

1 record

2008

1 record
What this brief cannot answer